OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.78
+0.04%Year over year
Reported trailing growth
- Revenue
- -2.5%
- EBITDA
- -13.9%
- EBIT
- -11.6%
- EPS
- -70.8%
- Free cash flow
- +3.3%
- Operating cash flow
- -10.8%
Forward estimates
Based on analyst estimates
- Revenue
- -1.2%
- EBITDA
- +46.3%
- EPS
- +340.5%
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -9.9%
- EBIT
- -9.0%
- Net income
- -41.1%
- EPS
- -41.6%
- Free cash flow
- +7.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026